Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01264211
Recruitment Status : Completed
First Posted : December 21, 2010
Last Update Posted : November 5, 2015
Information provided by (Responsible Party):
TRB Chemedica

Brief Summary:

To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA.

To evaluate the safety of Diacerein 100 mg daily when administrated in combination with oral MTX therapy in those patients for up to 24 weeks

To investigate a potential persistent effect, 4 weeks after Diacerein treatment is stopped (carry-over effect)

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Diacerein Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study
Study Start Date : October 2010
Actual Primary Completion Date : June 2012
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Diacerein Drug: Diacerein
Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks

Placebo Comparator: Placebo Drug: Placebo
Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks

Primary Outcome Measures :
  1. Percentage of patients with ACR20 response criteria [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Percentage of patients achieving a moderate response according to EULAR response criteria (changes in DAS28 score) [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female aged between 18 and 65 years;
  2. Active RA of ≥ 3 months duration but < 2 years, diagnosed according to the American College of Rheumatology (ACR) 1987 revised criteria for RA;
  3. RA global functional status class I-III;
  4. Treatment on an outpatient basis;
  5. Treatment with MTX for a minimum of 12 weeks, with stable weekly dose (10-20 mg) for at least 4 weeks before randomisation;
  6. Insufficient response to treatment with MTX, with disease activity score DAS28 > 4.0 at the time of screening and randomisation; the DAS28 must not change significantly from screening to baseline visit (change < 0.6);
  7. Tender joint count (TJC) ≥ 6 (68 joint count) and swollen joint count (SJC) ≥ 6 (66 joint count) at screening and randomisation;
  8. Screening ESR ≥ 28 mm/h;
  9. Evidence of adequate contraceptive methods in women of childbearing potential. Female patients of childbearing potential are those who are not surgically sterile or post-menopausal. Adequate contraceptive methods are hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the entire duration of the study;
  10. Agreement not to drink alcohol for the duration of the study;
  11. Ability and agreement to comply with the requirements of the study protocol;
  12. Having given written informed consent to participate in the study.

Exclusion Criteria:

  1. History of active inflammatory arthritis other than RA;
  2. Any uncontrolled medical condition such as diabetes mellitus, asthma, cardiopulmonary disease, congestive heart failure, neurological disease, etc.;
  3. Alcohol abuse, defined as the consumption of more than one glass of beer or wine in a day;
  4. Moderate or severe liver disease (cirrhosis, hepatitis, liver insufficiency);
  5. Blood anomalies (significant cytopenia);
  6. History of, or currently active primary or secondary immunodeficiency;
  7. Chronic hepatitis B (HBsAg positive or HBcAb positive with HBV DNA load ≥ 400 copies/ml) or hepatitis C (anti-HCV positive);
  8. Current known active, or history of, recurrent bacterial, viral, fungal, mycobacterial or other infections, or any infection requiring hospitalisation or treatment with i.v. antibiotics within 4 weeks prior to randomisation or oral antibiotics within 2 weeks prior to randomisation;
  9. Treatment with biologic DMARDs such as TNF antagonists, IL 1 receptor antagonists, IL 6 receptor antagonists, CTLA4Ig within 12 weeks prior to randomisation, and rituximab within 24 weeks prior to randomisation;
  10. Treatment with non-biologic DMARDs such as chloroquine, hydroxychloroquine, penicillamine, sulfasalazine within 4 weeks prior to randomisation, leflunomide, parenteral gold, oral gold within 8 weeks prior to randomisation, azathioprine and ciclosporin within 12 weeks prior to randomisation;
  11. Treatment with intra-articular injection of a depocorticosteroid within 8 weeks prior to randomisation;
  12. Treatment with NSAID or oral corticosteroids, unless the patient has been on a stable dose for at least 4 weeks before randomisation (maximal allowed daily dose of oral corticosteroid equivalent to prednisone 10 mg);
  13. Physical therapy and alternative therapies, unless the patient has received them regularly for at least 4 weeks before randomisation;
  14. Initiation of chronic treatment with antihistaminics, antidepressants or tranquilisers, within less than 12 weeks before randomisation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01264211

Layout table for location information
Juree Rawdmanee
Sukhumvit, Bangkok, Thailand, 10110
Faculty of medicine, Chiangmai University
Chiangmai, Thailand, 50002
Sponsors and Collaborators
TRB Chemedica
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: TRB Chemedica Identifier: NCT01264211    
Other Study ID Numbers: DAR-THA-05-01
First Posted: December 21, 2010    Key Record Dates
Last Update Posted: November 5, 2015
Last Verified: November 2015
Keywords provided by TRB Chemedica:
Efficacy of Diacerein
Safety of Diacerein
Carry-over effect of Diacerein
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents